An important role of lymphatic vessel activation in limiting acute inflammation

Blood

Volumn 117, Issue 17, 2011, Pages 4667-4678

  Huggenberger, Reto ^a   Siddiqui, Shoib S ^a   Brander, Daniela ^a   Ullmann, Stefan ^a   Zimmermann, Kathrin ^a   Antsiferova, Maria ^a   Werner, Sabine ^a   Alitalo, Kari ^b   Detmar, Michael ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 14; CYTOKINE; MESSENGER RNA; OXAZOLONE; PROTEIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; EAR; GENE EXPRESSION; INFLAMMATORY INFILTRATE; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; SKIN; SKIN EDEMA; SKIN INFLAMMATION; TRANSGENIC ANIMAL; ULTRAVIOLET B RADIATION;

EID: 79955957828     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-316356     Document Type: Article

References (50)

1. Halin C, Detmar M. Inflammation, angiogenesis, and lymphangiogenesis. Methods Enzymol. 2008;445:1-25.
2. Bainbridge J, Sivakumar B, Paleolog E. Angiogenesis as a therapeutic target in arthritis: lessons from oncology. Curr Pharm Des. 2006; 12(21):2631-2644.
3. Baluk P, Tammela T, Ator E, et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest. 2005; 115(2):247-257. (Pubitemid 40385467)
4. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006;130(7):2060-2073. (Pubitemid 43816964)
5. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994;180(3):1141-1146. (Pubitemid 24256627)
6. Halin C, Tobler NE, Vigl B, Brown LF, Detmar M. VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. Blood. 2007;110(9):3158-3167. (Pubitemid 350106307)
7. Hirakawa S, Fujii S, Kajiya K, Yano K, Detmar M. Vascular endothelial growth factor promotes sensitivity to ultraviolet B-induced cutaneous photodamage. Blood. 2005;105(6):2392-2399. (Pubitemid 40387036)
8. Kajiya K, Hirakawa S, Detmar M. Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function. Am J Pathol. 2006;169(4):1496-1503. (Pubitemid 351194380)
9. Kunstfeld R, Hirakawa S, Hong YK, et al. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood. 2004;104(4): 1048-1057. (Pubitemid 39038025)
10. Schonthaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci U S A. 2009;106(50):21264-21269.
11. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 2003;102(1):161-168. (Pubitemid 36759650)
12. Huggenberger R, Ullmann S, Proulx ST, Pytowski B, Alitalo K, Detmar M. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med. 2010;207(10): 2255-2269.
13. Guo R, Zhou Q, Proulx ST, et al. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis Rheum. 2009;60(9):2666-2676.
14. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45(8):2666-2673. (Pubitemid 38998863)
15. Kerjaschki D, Regele HM, Moosberger I, et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol. 2004;15(3):603-612. (Pubitemid 38294790)
16. Podgrabinska S, Kamalu O, Mayer L, et al. Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism. J Immunol. 2009;183(3):1767-1779.
17. Kerjaschki D. Lymphatic neoangiogenesis in renal transplants: a driving force of chronic rejection? J Nephrol. 2006;19(4):403-406. (Pubitemid 44823194)
18. Cueni LN, Detmar M. New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol. 2006; 126(10):2167-2177. (Pubitemid 44413162)
19. Ruddle NH, Akirav EM. Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response. J Immunol. 2009;183(4):2205-2212.
20. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell. 140(4):460-476.
21. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92(8):3566-3570.
22. Haiko P, Makinen T, Keskitalo S, et al. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol Cell Biol. 2008; 28(15):4843-4850.
23. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276(5317):1423-1425. (Pubitemid 27235412)
24. Makinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001;7(2):199-205. (Pubitemid 32148487)
25. Kripke ML. Ultraviolet radiation and immunology: something new under the sun - presidential address. Cancer Res. 1994;54(23):6102-6105.
26. Takigawa M, Miyachi Y, Toda K, Yoshioka A. Mechanisms of contact photosensitivity in mice: IV. Antigen-specific suppressor T cells induced by preirradiation of photosensitizing site to UVB. J Immunol. 1984;132(3):1124- 1129. (Pubitemid 14155346)
27. Keuschnigg J, Henttinen T, Auvinen K, Karikoski M, Salmi M, Jalkanen S. The prototype endothelial marker PAL-E is a leukocyte trafficking molecule. Blood. 2009;114(2):478-484.
28. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-1108. (Pubitemid 351818697)
29. Kumin A, Huber C, Rulicke T, Wolf E, Werner S. Peroxiredoxin 6 is a potent cytoprotective enzyme in the epidermis. Am J Pathol. 2006;169(4): 1194-1205. (Pubitemid 351194356)
30. Liao S, Ruddle NH. Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. J Immunol. 2006;177(5):3369-3379. (Pubitemid 44277857)
31. Lohela M, Helotera H, Haiko P, Dumont DJ, Alitalo K. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues. Am J Pathol. 2008; 173(6):1891-1901.
32. Asherson GL, Zembala M. Contact sensitivity in the mouse: IV. The role of lymphocytes and macrophages in passive transfer and the mechanism of their interaction. J Exp Med. 1970;132(1): 1-15.
33. Yano K, Kajiya K, Ishiwata M, Hong YK, Miyakawa T, Detmar M. Ultraviolet B-induced skin angiogenesis is associated with a switch in the balance of vascular endothelial growth factor and thrombospondin-1 expression. J Invest Dermatol. 2004;122(1):201-208. (Pubitemid 38114657)
34. McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med. 2001;164(10):S39-S45.
35. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004; 113(7):1040-1050. (Pubitemid 38544126)
36. Kerjaschki D, Huttary N, Raab I, et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med. 2006;12(2):230-234. (Pubitemid 43214751)
37. Baldwin ME, Catimel B, Nice EC, et al. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man. J Biol Chem. 2001;276(22):19166-19171.
38. Partanen TA, Arola J, Saaristo A, et al. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J. 2000;14(13): 2087-2096.
39. Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997;16(13):3898-3911. (Pubitemid 27281006)
40. Hamrah P, Chen L, Zhang Q, Dana MR. Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-C on corneal dendritic cells. Am J Pathol. 2003;163(1):57-68. (Pubitemid 36759591)
41. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008; 454(7204):656-660.
42. Flister MJ, Wilber A, Hall KL, et al. Inflammation induces lymphangiogenesis through upregulation of VEGFR-3 mediated by NF-κB and Prox1. Blood. 2010;115(2):418-429.
43. Hong YK, Harvey N, Noh YH, et al. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn. 2002; 225(3):351-357. (Pubitemid 35265813)
44. Pan MR, Chang TM, Chang HC, Su JL, Wang HW, Hung WC. Sumoylation of Prox1 controls its ability to induce VEGFR3 expression and lymphatic phenotypes in endothelial cells. J Cell Sci. 2009;122(18):3358-3364.
45. Petrova TV, Makinen T, Makela TP, et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J. 2002;21(17):4593-4599. (Pubitemid 34984346)
46. Kajiya K, Sawane M, Huggenberger R, Detmar M. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis. J Invest Dermatol. 2009;129(5): 1292-1298.
47. Kajiya K, Detmar M. An important role of lymphatic vessels in the control of UVB-induced edema formation and inflammation. J Invest Dermatol. 2006;126(4):919-921.
48. + macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood. 2009;113(22): 5650-5659.
49. Jamieson T, Cook DN, Nibbs RJ, et al. The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol. 2005;6(4): 403-411. (Pubitemid 41716781)
50. Harwood CA, Mortimer PS. Causes and clinical manifestations of lymphatic failure. Clin Dermatol. 1995;13(5):459-471. (Pubitemid 26073916)